Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Two Physicians Treat Most Residents With HIV In Southeastern Wyoming
The Casper Star-Tribune profiled Carol Fischer and Mark Dowell, the only two physicians in southeastern Wyoming that treat large numbers of people with HIV. There are more than 100 people in Wyoming living with HIV, according to the state Department of Health, and Fischer and Dowell treat most of them, the Star-Tribune reports. Fischer has been deemed the "de facto AIDS doctor" in the area as she received no formal training on HIV, but Dowell is an expert on the disease who became the state"s first full-time infectious disease specialist (Miller, Casper Star-Tribune, 6/7). Don't forget to buy zoloft online no prescription.

Stem Cell Industry Expert Praises, Encourages Continued Progress On Legislation To Promote Benefits Of Cord Blood
Mercedes Walton, CEO of Cryo-Cell International, one of the largest and most established family cord blood banks, is praising legislative progress to date and encouraging continued momentum for existing bills through the second half of the year. H.R. 1718, the "Family Cord Blood Banking Act," and H.R. 2107, the "Cord Blood Education and Awareness Act of 2009" would continue to build on the progress from the first half of the year to enable and promote the continued research, public awareness and tax benefits related to storing and using cord blood, all of which provide great benefit to families across America.

generic viagra online


News of the day
Doctors Struggle To Find Teaching Time, Australia
Due to workforce shortages, doctors are struggling to maintain their involvement in teaching and in research activities, according to an article published in the Medical Journal of Australia. Further, the demands for doctors to teach medical students and doctors-in-training are increasing, with even more medical students now enrolled.
Medical Devices

FDA Approves Feraheme™ To Treat Iron Deficiency Anemia In Adult Chronic Kidney Disease Patients

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme™ (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. The recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg IV injection three to eight days later. Feraheme should be administered as an undiluted IV injection delivered at a rate of up to 1 mL/sec (30 mg/sec). The recommended Feraheme dose may be readministered to patients with persistent or recurrent iron deficiency anemia. Feraheme is expected to be commercially available in the U.S. during the second half of July 2009. Feraheme will be distributed primarily through wholesalers and specialty distributors. The Company will market and sell Feraheme through its commercial organization consisting of approximately 150 seasoned professionals, including an 80-person specialized sales force, an experienced account management and reimbursement team, and a contract nurse team. "Feraheme offers patients across the continuum of chronic kidney disease, including patients not on dialysis and patients on dialysis, a new paradigm for the treatment of iron deficiency anemia," commented Brian J.G. Pereira, MD, President and Chief Executive Officer of AMAG. "We are extremely pleased with the FDA"s approval of Feraheme, and we are well prepared and excited to bring this new treatment option to patients and physicians." "Iron deficiency anemia is a significant problem in patients with chronic kidney disease and is frequently underdiagnosed and undertreated,1,2" said Bryan Becker, MD, President of the National Kidney Foundation. "We welcome the availability of a new therapy option for chronic kidney disease patients affected by iron deficiency anemia." Clinical Data Feraheme has been proven to be a safe and effective therapy for treating iron deficiency anemia in adult chronic kidney disease patients. The FDA approval of Feraheme was based on safety and efficacy results from four Phase III studies of patients with chronic kidney disease and iron deficiency anemia. These studies consisted of three open-label, multi-center, randomized safety and efficacy clinical studies and a fourth double-blind, multi-center, randomized, placebo-controlled cross-over safety study. Each of the three pivotal safety and efficacy studies achieved statistical significance in its primary endpoint: the mean change in hemoglobin from baseline at Day 35 after the first dose. Feraheme significantly increased hemoglobin levels as compared to oral iron across the spectrum of chronic kidney disease. Overall, 1,726 subjects were exposed to Feraheme in the development program, including 1,562 patients with all stages of chronic kidney disease. In accordance with the Pediatric Research Equity Act (PREA) requirement, the Company will conduct two post-marketing studies in the pediatric chronic kidney disease population; one in patients on dialysis and the other in patients not on dialysis. Each study will enroll approximately 75 subjects, collecting pharmacokinetic, safety and efficacy data as compared to oral iron. The Company expects to commence these studies in 2010. AMAG Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009